Literature DB >> 11837727

Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire.

W G Thompson1, E J Irvine, P Pare, S Ferrazzi, L Rance.   

Abstract

The Rome II criteria and questionnaires developed to identify functional gastrointestinal disorders have not been evaluated. Our objectives were to determine the prevalence of functional gastrointestinal disorders in Canada, compare our results with data from other published studies, assess concordance of Rome I and Rome II criteria for irritable bowel syndrome, and suggest improvements in the Rome II questionnaire. An independent research firm was employed to conduct a random digit dial national survey, inviting household members > or = 18 years of age to participate in a study examining personal health issues. Subjects recruited by telephone, who agreed to participate, were mailed a questionnaire, and the data were retrieved by a follow-up phone call. The Rome II questionnaire and algorithms were used and where possible Rome I algorithms were also applied. At least one functional gastrointestinal disorder occurred in 61.7% of 1149 respondents (65.6% female versus 57.6% male; P < 0.05). The most prevalent were the functional bowel disorders at 41.6% followed by esophageal disorders at 28.9%. Irritable bowel syndrome prevalence by Rome II and I criteria were 12.1% and 13.5%, respectively (kappa = 0.76). Because the Rome II criteria have added exclusion items that are not present in the Rome I criteria, the prevalence of esophageal, gastroduodenal, and anorectal disorders is lower than the figures from a US market survey. In conclusion, functional gastrointestinal disorders are highly prevalent in Canada, with a significantly higher rate in women. There is substantial agreement between Rome I and Rome II criteria for irritable bowel syndrome. Rome criteria and questionnaire remain works in progress.

Entities:  

Mesh:

Year:  2002        PMID: 11837727     DOI: 10.1023/a:1013208713670

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

2.  Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters.

Authors:  K W Heaton; L J O'Donnell; F E Braddon; R A Mountford; A O Hughes; P J Cripps
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

3.  Functional gastrointestinal symptoms in a Wellington community sample.

Authors:  G W Welch; E W Pomare
Journal:  N Z Med J       Date:  1990-09-12

4.  Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features.

Authors:  W F Stewart; J N Liberman; R S Sandler; M S Woods; A Stemhagen; E Chee; R B Lipton; C E Farup
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

5.  Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples.

Authors:  W E Whitehead; M D Crowell; L Bosmajian; A Zonderman; P T Costa; C Benjamin; J C Robinson; B R Heller; M M Schuster
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

6.  Demographic and dietary determinants of constipation in the US population.

Authors:  R S Sandler; M C Jordan; B J Shelton
Journal:  Am J Public Health       Date:  1990-02       Impact factor: 9.308

7.  Gender differences in irritable bowel symptoms.

Authors:  W G Thompson
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-03       Impact factor: 2.566

8.  Functional bowel disorders in apparently healthy people.

Authors:  W G Thompson; K W Heaton
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

9.  Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

Authors:  H Mertz; B Naliboff; J Munakata; N Niazi; E A Mayer
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Evidence for the ambiguity of the term constipation: the role of irritable bowel syndrome.

Authors:  C S Probert; P M Emmett; H A Cripps; K W Heaton
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

View more
  84 in total

Review 1.  When is irritable bowel syndrome not irritable bowel syndrome? Diagnosis and treatment of chronic functional abdominal pain.

Authors:  Madhusudan Grover
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

3.  Prevalence, impact and attitudes toward lower gastrointestinal dysmotility and sensory symptoms, and their treatment in Canada: A descriptive study.

Authors:  Richard H Hunt; Surinder Dhaliwal; Gervais Tougas; Carmen Pedro; Jean-Francois Labbé; Heidi Paul; Michael Ennamorato
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

4.  Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index.

Authors:  Masae Shinozaki; Motoyori Kanazawa; Yasuhiro Sagami; Yuka Endo; Michio Hongo; Douglas A Drossman; William E Whitehead; Shin Fukudo
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

Review 5.  Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment.

Authors:  P Paré; Ronald Bridges; Malcolm C Champion; Subhas C Ganguli; James R Gray; E Jan Irvine; Victor Plourde; Pierre Poitras; Geoffrey K Turnbull; Paul Moayyedi; Nigel Flook; Stephen M Collins
Journal:  Can J Gastroenterol       Date:  2007-04       Impact factor: 3.522

6.  Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact.

Authors:  Richard N Fedorak; Stephen J Vanner; William G Paterson; Ron J Bridges
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

7.  A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients.

Authors:  Kyung Sik Park; Sung Hun Ahn; Jae Seok Hwang; Kwang Bum Cho; Woo Jin Chung; Byung Kuk Jang; Yu Na Kang; Jung Hyeok Kwon; Young Hwan Kim
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

8.  Digestive symptoms in older adults: prevalence and associations with institutionalization and mortality.

Authors:  Turki Alameel; Mohammed Basheikh; Melissa K Andrew
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 9.  New developments in the diagnosis and treatment of irritable bowel syndrome.

Authors:  George F Longstreth; Douglas A Drossman
Journal:  Curr Gastroenterol Rep       Date:  2002-10

10.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.